Greilsamer Tristan, Blanchard Claire, Christou Niki, Drui Delphine, Ansquer Catherine, Le Bras Maelle, Cariou Bertrand, Caillard Cécile, Mourrain-Langlois Emmanuelle, Delemazure Anne Sophie, Mathonnet Muriel, Kraeber-Bodéré Françoise, Mirallié Eric
Clinique de Chirurgie Digestive et Endocrinienne (CCDE), Institut des Maladies de l'Appareil Digestif (IMAD), Centre Hospitalier Universitaire (CHU) Nantes-Hôtel Dieu, Place Alexis Ricordeau, 44093, Nantes, France.
Langenbecks Arch Surg. 2015 Apr;400(3):313-8. doi: 10.1007/s00423-015-1286-y. Epub 2015 Feb 20.
Parathyroid sestamibi scan is routinely performed before parathyroid surgery. A large number of thyroid cancers take up 99mTc-sestamibi (MIBI). Since 2001, thyroid nodules discovered on sestamibi, nodules >2 cm, and/or with suspicious criteria were resected. The aim of this study was to evaluate the results of this policy.
All patients operated on for hyperparathyroidism, with a MIBI and cervical ultrasonography (US) with a thyroid resection for nodule, were retrospectively included.
From 2001 to 2013, 685 patients were operated on for hyperparathyroidism. Some 137 (85 % females) had both preoperative MIBI and cervical US and a thyroid resection. The mean age was 63.2 ± 12.8 years. Sixty-three patients had a total thyroidectomy and 74 a lobectomy. Thirty-six patients had a thyroid cancer. The median size of cancers was 6.5 mm (0.3-22 mm), and 23 (16.7 %) patients had microcarcinoma. Among the 137 patients, 44 (32 %) had a MIBI+ nodule including 22 cancers. Sixty-one percent of malignant nodules were MIBI+ (22/36). The median size of MIBI+ cancers was 15 mm (9-22 mm) versus 2 mm (0.3-17 mm) for MIBI- cancers (p = 0.03). Twenty-two percent of benign nodules were MIBI+ (22/101). Finally, the sensitivity, specificity, positive predictive value, and negative predictive value of MIBI were 61, 78, 50, and 85 %, respectively.
Thyroid nodules incidentally discovered on MIBI in hyperparathyroidism patients should be resected.
甲状旁腺99m锝-甲氧基异丁基异腈(MIBI)扫描通常在甲状旁腺手术前进行。大量甲状腺癌会摄取99mTc-MIBI(MIBI)。自2001年以来,在MIBI检查中发现的甲状腺结节、直径大于2 cm的结节和/或具有可疑标准的结节均被切除。本研究的目的是评估这一策略的结果。
回顾性纳入所有因甲状旁腺功能亢进接受手术、进行了MIBI检查和颈部超声(US)检查并因结节行甲状腺切除术的患者。
2001年至2013年,685例患者因甲状旁腺功能亢进接受手术。其中约137例(85%为女性)术前行MIBI检查、颈部超声检查并进行了甲状腺切除术。平均年龄为63.2±12.8岁。63例患者行甲状腺全切术,74例患者行甲状腺叶切除术。36例患者患有甲状腺癌。癌灶的中位大小为6.5 mm(0.3 - 22 mm),23例(16.7%)患者为微小癌。在这137例患者中,44例(32%)有MIBI阳性结节,其中包括22例癌灶。61%的恶性结节为MIBI阳性(22/36)。MIBI阳性癌灶的中位大小为15 mm(9 - 22 mm),而MIBI阴性癌灶的中位大小为2 mm(0.3 - 17 mm)(p = 0.03)。22%的良性结节为MIBI阳性(22/101)。最后,MIBI的敏感性、特异性、阳性预测值和阴性预测值分别为61%、78%、50%和85%。
甲状旁腺功能亢进患者在MIBI检查中偶然发现的甲状腺结节应予以切除。